Microviable Therapeutics, through our CEO Rafael Martínez Permuy, was part of the “Gut Microbiota for Health World Summit” (#GMFH2020) that was held on March 7 and 8 in Madrid, a great international event on microbiota that has recorded 200 attendees in person plus some others by videoconference (videoconference due to travel restrictions).
El Comercio (Diario de Asturias), highlights Microviable’s activity in “the long-term isolation and storage of the microbiota under viable conditions, the analysis of its composition and, finally, the development of microbiome-based therapies. The first two business lines of Microviable, the collection of faecal samples guaranteeing the anaerobiosis (absence of oxygen) conditions with the patented GutAlive device, and the storage service, are already fully active. The GutAlive kit sales already reach five countries and more than half of the researchers or clinicians who know it, want to try it.
